CSPC obtains approval for cobamamide capsules in China

CSPC Pharmaceutical Group Limited (HKEX:1093) announced that its Cobamamide Capsules (0.5mg) have received drug registration approval from the National Medical Products Administration of the People's Republic of China. The capsules are a type of Vitamin B12 drug. The approval confirms that the drugs have passed quality and efficacy evaluations. Indicated for treating megaloblastic anemia, nutritional anemia, anemia during pregnancy, polyneuritis, radiculitis, trigeminal neuralgia, sciatica, and nerve palsy, the drug can also be used as an adjunct therapy for nutritional disorders and leukopenia caused by radiation and drugs. The company expects this approval to strengthen its product portfolio in the therapeutic areas of hematology and neurology.